- AstraZeneca is investing $3.5B in U.S. research and manufacturing sites by 2026, focusing on R&D, biologics, and cell therapy manufacturing.
- This investment is expected to add over 1K skilled jobs, making the U.S. key to the company’s global growth strategy.
- The funding targets facilities in Kendall Square, MD, Texas, and the East and West Coasts, solidifying AstraZeneca’s presence in top U.S. life sciences hubs.
As reported in Bisnow, AstraZeneca (AZN), the British biopharma giant, announced plans to invest $3.5B in the U.S. by 2026 to support its growing research, development, and manufacturing footprint.
Zooming Out
This expansion will include a research and development center in Boston’s Kendall Square, a biologics manufacturing site in Maryland, specialty manufacturing in Texas, and new cell therapy facilities on both coasts.
While specific facilities have not yet been identified, this commitment represents a substantial increase in the company’s U.S. presence, which currently spans 17 sites in 12 states.
AstraZeneca CEO Pascal Soriot emphasized that the U.S. business climate, talent pool, and innovative capacity make it a top destination for the company’s latest investments.
The expansion is set to create over 1K high-skilled jobs and strengthen AstraZeneca’s capacity for developing advanced therapies, supporting the U.S. role as a global leader in healthcare innovation.
Track Record
AstraZeneca’s U.S. investments follow a series of recent expansions, including a $300M investment announced in February to convert an 85 KSF Rockville, MD facility into a manufacturing site and a lease on a 198 KSF industrial building in Gaithersburg, MD.
In Kendall Square, the company pre-leased space in one of BXP’s two 16-story life sciences towers, set to house 1.5K employees upon completion in 2026.
Get Smarter about what matters in CRE
Stay ahead of trends in commercial real estate with CRE Daily – the free newsletter delivering everything you need to start your day in just 5-minutes
Subscribe
Rising Revenues
AstraZeneca’s U.S. workforce currently includes about 17.8K employees, supporting strong revenue growth. The company posted Q3 revenue of $13.57B, up 19% from last year, and YTD revenue of $39.2B—a 21% increase.
This new investment positions AstraZeneca for further growth, building upon its recent achievements in revenue and workforce expansion.
Broader Impact
AstraZeneca’s expansion supports continued momentum in the U.S. life sciences sector, where demand for advanced research and manufacturing facilities remains high.
As the company strengthens its footprint in key regions, including Boston, Maryland, and Texas, these investments are expected to drive local economic growth and attract further investment to leading biotech hubs across the nation.
